Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Novelli S, Briones J, Sierra J. Epidemiology of lymphoid malignancies: last decade update. Springerplus. 2013;2:70.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Y, Wang Z, et al. Racial differences in three major NHL subtypes: descriptive epidemiology. Cancer Epidemiol. 2015;39:8–13.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861–1874.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Gisselbrecht C. Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr Oncol Rep. 2009;11:386–393.
   PubMed Web of Science ®Google Scholar
• Carella AM, de Souza CA, Luminari S, et al. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study. Leuk Lymphoma. 2013;54:53–57.
   PubMed Web of Science ®Google Scholar
• Riihijarvi S, Taskinen M, Jerkeman M, et al. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol. 2010;86:124–128.
   PubMed Web of Science ®Google Scholar
• Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma. 2008;49:462–469.
   PubMed Web of Science ®Google Scholar
• Yildirim M, Kaya V, Demirpence O, et al. The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis. Arch Med Sci. 2015;11:708–714.
   PubMed Web of Science ®Google Scholar
• Hedstrom G, Peterson S, Berglund M, et al. Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma – a Swedish population-based study. Acta Oncol. 2015;54:924–932.
   PubMed Web of Science ®Google Scholar
• Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate- or high-grade B-cell non-Hodgkin’s lymphoma in women. J Clin Oncol. 2001;19:1381–1387.
   PubMed Web of Science ®Google Scholar
• Lee JS, Bracci PM, Holly EA. Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use. Am J Epidemiol. 2008;168:278–288.
   PubMed Web of Science ®Google Scholar
• Prescott J, Lu Y, Chang ET, et al. Reproductive factors and non-Hodgkin lymphoma risk in the California Teachers Study. PLoS One. 2009;4:e8135.
   PubMed Web of Science ®Google Scholar
• Yakimchuk K, Iravani M, Hasni MS, et al. Effect of ligand-activated estrogen receptor β on lymphoma growth in vitro and in vivo. Leukemia. 2011;25:1103–1110.
   PubMed Web of Science ®Google Scholar
• Yakimchuk K, Jondal M, Okret S. Estrogen receptor α and β in the normal immune system and in lymphoid malignancies. Mol Cell Endocrinol. 2013;375:121–129.
   PubMed Web of Science ®Google Scholar
• Strom A, Hartman J, Foster JS, et al. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA. 2004;101:1566–1571.
   PubMed Web of Science ®Google Scholar
• Hartman J, Lindberg K, Morani A, et al. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006;66:11207–11213.
   PubMed Web of Science ®Google Scholar
• Warner M, Gustafsson JA. The role of estrogen receptor beta (ERbeta) in malignant diseases-a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun. 2010;396:63–66.
   PubMed Web of Science ®Google Scholar
• Bardin A, Hoffmann P, Boulle N, et al. Involvement of estrogen receptor beta in ovarian carcinogenesis. Cancer Res. 2004;64:5861–5869.
   PubMed Web of Science ®Google Scholar
• Cheng J, Lee EJ, Madison LD, et al. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. 2004;566:169–172.
   PubMed Web of Science ®Google Scholar
• Cookman CJ, Belcher SM. Estrogen receptor beta upregulates IGF1R expression and activity to inhibit apoptosis and increase growth of medulloblastoma. Endocrinology. 2015;156:2395–2408.
   PubMed Web of Science ®Google Scholar
• Jonsson P, Katchy A, Williams C. Support of a bi-faceted role of estrogen receptor beta (ERbeta) in ERalpha-positive breast cancer cells. Endocr Relat Cancer. 2014;21:143–160.
   PubMed Web of Science ®Google Scholar
• Leung YK, Mak P, Hassan S, et al. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA. 2006;103:13162–13167.
   PubMed Web of Science ®Google Scholar
• Yakimchuk K, Hasni MS, Guan J, et al. Inhibition of lymphoma vascularization and dissemination by estrogen receptor β agonists. Blood. 2014;123:2054–2061.
   PubMed Web of Science ®Google Scholar
• Amini RM, Berglund M, Rosenquist R, et al. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma. 2002;43:2179–2189.
   PubMed Web of Science ®Google Scholar
• Epstein AL, Kaplan HS. Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines. Cancer Res. 1979;39:1748–1759.
   PubMed Web of Science ®Google Scholar
• Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174:6477–6489.
   PubMed Web of Science ®Google Scholar
• Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83–87.
   PubMedGoogle Scholar
• Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1989;72:141–149.
   PubMed Web of Science ®Google Scholar
• Talaber G, Yakimchuk K, Guan J, et al. Inhibition of estrogen biosynthesis enhances lymphoma growth in mice. Oncotarget. 2016;7:20718–20727.
   PubMed Web of Science ®Google Scholar
• Chen L, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23:826–838.
   PubMed Web of Science ®Google Scholar
• Pinton G, Manente AG, Daga A, et al. Agonist activation of estrogen receptor beta (ERbeta) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. Mol Cancer. 2014;13:227.
   PubMed Web of Science ®Google Scholar
• Sareddy GR, Nair BC, Gonugunta VK, et al. Therapeutic significance of estrogen receptor β agonists in gliomas. Mol Cancer Ther. 2012;11:1174–1182.
   PubMed Web of Science ®Google Scholar
• Bardin A, Boulle N, Lazennec G, et al. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11:537–551.
   PubMed Web of Science ®Google Scholar
• Rody A, Holtrich U, Solbach C, et al. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer. 2005;12:903–916.
   PubMed Web of Science ®Google Scholar
• Rosin G, de Boniface J, Karthik GM, et al. Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis. Br J Cancer. 2014;111:918–926.
   PubMed Web of Science ®Google Scholar
• Heikkila A, Hagstrom J, Maenpaa H, et al. Loss of estrogen receptor beta expression in follicular thyroid carcinoma predicts poor outcome. Thyroid. 2013;23:456–465.
   PubMed Web of Science ®Google Scholar
• Pinton G, Brunelli E, Murer B, et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009;69:4598–4604.
   PubMed Web of Science ®Google Scholar
• Reese JM, Suman VJ, Subramaniam M, et al. ERbeta1: characterization, prognosis, and evaluation of treatment strategies in ERalpha-positive and -negative breast cancer. BMC Cancer. 2014;14:749.
   PubMed Web of Science ®Google Scholar
• Rudolph A, Toth C, Hoffmeister M, et al. Expression of oestrogen receptor β and prognosis of colorectal cancer. Br J Cancer. 2012;107:831–839.
   PubMed Web of Science ®Google Scholar
• Riihijarvi S, Fiskvik I, Taskinen M, et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica. 2015;100:238–245.
   PubMed Web of Science ®Google Scholar
• Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2009;100:1842–1847.
   PubMed Web of Science ®Google Scholar
• Frei E, Visco C, Xu-Monette ZY, et al. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin Pathol. 2013;66:956–961.
   PubMed Web of Science ®Google Scholar
• Ciucci A, Zannoni GF, Travaglia D, et al. Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer. Gynecol Oncol. 2014;132:351–359.
   PubMed Web of Science ®Google Scholar
• Shaaban AM, Green AR, Karthik S, et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res. 2008;14:5228–5235.
   PubMed Web of Science ®Google Scholar
• Yakimchuk K, Norin S, Kimby E, et al. Up-regulated estrogen receptor beta2 in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:139–144.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar